Part of a series on |
Purinergic signalling |
---|
Concepts |
Membrane transporters |
P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as adenosine triphosphate, adenosine diphosphate, uridine triphosphate, uridine diphosphate and UDP-glucose.To date, 8 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14. [1]
P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y receptors mediate responses including vasodilation, [2] blood clotting, [3] and immune response. [4] Due to their ubiquity and variety in function, they are a common biological target in pharmacological development. [3]
P2Y receptors are membrane proteins belonging to the class A family of G protein-coupled receptors (GPCRs). [5] [6] P2Y receptor proteins display large-scale structural domains typical of GPCRs, consisting of seven hydrophobic transmembrane helices connected by three short extracellular loops and three variably sized intracellular loops; an extracellular N-terminus; and an intracellular C-terminus. [7] The extracellular regions interact with the receptor ligands, while the intracellular regions activate the G protein, control receptor internalization, and mediate dimerization. [6] Similar to other GPCRs, P2Y receptors can form both homodimers and heterodimers. These dimeric forms may vary significantly in their biochemical and pharmacological properties from the monomeric receptor.
In addition to the structural domains typical of all GPCRs, some structural elements are common across P2Y receptor subtypes. All P2Y receptors contain four extracellular cysteine residues which can form two disulfide bridges, one between the N-terminus domain and the proximal extracellular loop and another between the two remaining extracellular loops. [6] These disulfide bonds have been shown to be involved in ligand binding and signal transduction. [8] In addition, several polar residues found within the transmembrane helices are highly conserved across both species and receptor subtypes. Mutational analysis has suggested that these residues are integral to the ligand-binding mechanism of P2Y receptors. Outside of these conserved regions, the P2Y receptor family exhibits unusually high diversity in primary structure, with P2Y1 sharing only 19% of its primary structure with P2Y12. [6] Despite this, the individual P2Y subtypes are highly conserved across species, with human and mouse P2Y receptors sharing 95% of amino acids.
The ligand-binding mechanisms of P2Y receptors are not currently well established. [8] The binding complex of P2Y receptors with ATP is of significant interest, as no P2Y receptor contains amino acids sequences similar to any of the many established ATP-binding sites. [7] Recent x-ray crystallography of the human P2Y12 receptor has shown several structural irregularities in regions that are typically highly conserved across GPCRs. [8]
In contrast to the unusual structure and behavior of the extracellular ligand binding domains, P2Y intracellular domains appear to be structurally and mechanistically similar to other GPCRs. [6]
P2Y receptors respond either positively or negatively to the presence of nucleotides in extracellular solution. [9] Nucleotides may be divided into two categories: purines and pyrimidines. Individual P2Y receptor species may respond to only purines, only pyrimidines, or both; the activation profiles of the eight known P2Y receptors are listed below. [9]
P2Y species | Receptivity |
---|---|
P2Y1 | Activation by purines [9] |
P2Y2 | Activation by purines and pyrimidines triphosphates [9] |
P2Y4 | Activation by pyrimidines [9] |
P2Y6 | Activation by pyrimidines [9] |
P2Y11 | Activation by purines [9] |
P2Y12 | Inactivation by ADP through G1 protein [9] |
P2Y13 | Inactivation by ADP through G1 protein [9] |
P2Y14 | Activation by UDP-Glucose [9] |
The activity of P2Y receptors is linked to a signal cascade originating in regulation of the flow of Ca2+ and K+ ions by the receptor's interactions with G proteins, modulating access to Ca2+ and K+ channels, though the exact behavior is dependent upon individual receptor species. [10] Voltage-independent Ca2+ channels allow for the free flow of Ca2+ ions from the cell activated by P2Y receptors. [10] Oscillation of Ca2+ concentration is directly affected by the signal-transduction activity of P2Y1; specifically, through protein kinase C phosphorylation of Thr339 in the carboxy terminus of the P2Y1 receptor. [10]
Changes in the concentration of Ca2+ have many important ramifications for the cell, including regulation of cell metabolism (e.g. autophagy initiation / regulation), ATP production (through Ca2+ entering the mitochondrial outer mitochondrial membrane and stimulation of mitochondrial dehydrogenases leading to the production of ATP), and the possibility of triggering apoptosis. [11] [12] Both autophagy and apoptosis are cell stress responses that play significant roles in cells' overall life cycles, though autophagy seeks to preserve the viability of the cell by recycling unit parts of organelles, while apoptosis acts in the interest of the whole organism at the expense of the cell undergoing apoptosis. [12]
Many commonly prescribed medications target P2Y receptors, and active research is being conducted into developing new drugs targeting these receptors. [3] The most commonly prescribed drug targeting P2Y receptors is clopidogrel, an antiplatelet medication which acts on the P2Y12 receptor in a manner shared with other thienopyridines. [14] Other pharmaceutical applications include denufosol, which targets P2Y2 and is being investigated for the treatment of cystic fibrosis, and diquafosol, a P2Y2 agonist used in the treatment of dry eye disease. [15] [16] [17]
P2Y6 receptors have been shown to play a role in cerebral vasodilation. UDP-analogs which bind to this receptor have been investigated as possible treatments for migraines. [18] [17]
P2Y11 is a regulator of immune response, and a common polymorphism carried by almost 20% of North European caucasians give increased risk of myocardial infarction, making P2Y11 an interesting drug target candidate for treatment of myocardial infarction. [4] [16] [17]
In addition to established uses, pharmaceutical research has been conducted into the role of P2Y receptors in osteoporosis, [2] diabetes, [19] and cardio-protection. [20] [17]
The biological effects of P2Y receptor activation depends on how they couple to downstream signalling pathways, either via Gi, Gq/11 or Gs G proteins. Human P2Y receptors have the following G protein coupling: [21]
Protein | Gene | Coupling | Nucleotide |
P2RY1 | P2RY1 | Gq/11 | ADP |
P2RY2 | P2RY2 | Gq/11 (and Gi) | ATP, UTP |
P2RY4 | P2RY4 | Gq/11 (and Gi) | UTP |
P2RY5 / LPA6 | LPAR6 | Lysophosphatidic acid [22] | |
P2RY6 | P2RY6 | Gq/11 | UDP |
P2RY8 | P2RY8 | orphan receptor | |
P2RY9 / LPAR4 / GPR23 | LPAR4 | Lysophosphatidic acid | |
P2RY10 | P2RY10 | orphan receptor | |
P2RY11 | P2RY11 | Gq/11 and Gs | ATP |
P2RY12 | P2RY12 | Gi | ADP |
P2RY13 | P2RY13 | Gi | ADP |
P2RY14 | P2RY14 | Gi | UDP-glucose |
The gaps in P2Y receptor numbering is due to that several receptors (P2Y3, P2Y5, P2Y7, P2Y8, P2Y9, P2Y10) were thought to be P2Y receptors when they were cloned, when in fact they are not.
G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptors, and G protein-linked receptors (GPLR), form a large group of evolutionarily related proteins that are cell surface receptors that detect molecules outside the cell and activate cellular responses. They are coupled with G proteins. They pass through the cell membrane seven times in form of six loops of amino acid residues, which is why they are sometimes referred to as seven-transmembrane receptors. Ligands can bind either to the extracellular N-terminus and loops or to the binding site within transmembrane helices. They are all activated by agonists, although a spontaneous auto-activation of an empty receptor has also been observed.
In biochemistry and pharmacology, receptors are chemical structures, composed of protein, that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to a receptor and produce physiological responses such as change in the electrical activity of a cell. For example, GABA, an inhibitory neurotransmitter inhibits electrical activity of neurons by binding to GABAA receptors. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway.
Second messengers are intracellular signaling molecules released by the cell in response to exposure to extracellular signaling molecules—the first messengers. Second messengers trigger physiological changes at cellular level such as proliferation, differentiation, migration, survival, apoptosis and depolarization.
In biology, cell signaling or cell communication is the ability of a cell to receive, process, and transmit signals with its environment and with itself. Cell signaling is a fundamental property of all cellular life in prokaryotes and eukaryotes. Signals that originate from outside a cell can be physical agents like mechanical pressure, voltage, temperature, light, or chemical signals. Cell signaling can occur over short or long distances, and as a result can be classified as autocrine, juxtacrine, intracrine, paracrine, or endocrine. Signaling molecules can be synthesized from various biosynthetic pathways and released through passive or active transports, or even from cell damage.
P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene.
Purinergic receptors, also known as purinoceptors, are a family of plasma membrane molecules that are found in almost all mammalian tissues. Within the field of purinergic signalling, these receptors have been implicated in learning and memory, locomotor and feeding behavior, and sleep. More specifically, they are involved in several cellular functions, including proliferation and migration of neural stem cells, vascular reactivity, apoptosis and cytokine secretion. These functions have not been well characterized and the effect of the extracellular microenvironment on their function is also poorly understood.
The P2X receptors, also ATP-gated P2X receptor cation channel family, is a protein family that consists of cation-permeable ligand-gated ion channels that open in response to the binding of extracellular adenosine 5'-triphosphate (ATP). They belong to a larger family of receptors known as the ENaC/P2X superfamily. ENaC and P2X receptors have similar 3-D structures and are homologous. P2X receptors are present in a diverse array of organisms including humans, mouse, rat, rabbit, chicken, zebrafish, bullfrog, fluke, and amoeba.
Ectonucleotidases consist of families of nucleotide metabolizing enzymes that are expressed on the plasma membrane and have externally oriented active sites. These enzymes metabolize nucleotides to nucleosides. The contribution of ectonucleotidases in the modulation of purinergic signaling depends on the availability and preference of substrates and on cell and tissue distribution.
P2Y purinoceptor 1 is a protein that in humans is encoded by the P2RY1 gene.
P2Y purinoceptor 2 is a protein that in humans is encoded by the P2RY2 gene.
Uracil nucleotide/cysteinyl leukotriene receptor is a G protein-coupled receptor that in humans is encoded by the GPR17 gene located on chromosome 2 at position q21. The actual activating ligands for and some functions of this receptor are disputed.
P2Y purinoceptor 6 is a protein that in humans is encoded by the P2RY6 gene.
P2Y purinoceptor 11 is a protein that in humans is encoded by the P2RY11 gene.
P2Y purinoceptor 14 is a protein that in humans is encoded by the P2RY14 gene.
Lysophosphatidic acid receptor 6, also known as LPA6, P2RY5 and GPR87, is a protein that in humans is encoded by the LPAR6 gene. LPA6 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA).
2-Oxoglutarate receptor 1 (OXGR1), also known as cysteinyl leukotriene receptor E (CysLTE) and GPR99, is a protein that in humans is encoded by the OXGR1 gene. The Gene has recently been nominated as a receptor not only for 2-oxogluterate but also for the three cysteinyl leukotrienes (CysLTs), particularly leukotriene E4 (LTE4) and to far lesser extents LTC4 and LTE4. Recent studies implicate GPR99 as a cellular receptor which is activated by LTE4 thereby causing these cells to contribute to mediating various allergic and hypersensitivity responses.
Putative P2Y purinoceptor 10 is a protein that, in humans, is encoded by the P2RY10 gene.
P2Y purinoceptor 4 is a protein that in humans is encoded by the P2RY4 gene.
P2 receptor may refer to:
Purinergic signalling is a form of extracellular signalling mediated by purine nucleotides and nucleosides such as adenosine and ATP. It involves the activation of purinergic receptors in the cell and/or in nearby cells, thereby regulating cellular functions.